205 related articles for article (PubMed ID: 20874255)
1. Natalizumab therapy of multiple sclerosis.
Hutchinson M
J Interferon Cytokine Res; 2010 Oct; 30(10):787-9. PubMed ID: 20874255
[TBL] [Abstract][Full Text] [Related]
2. Neuronal injury in chronic CNS inflammation.
Zindler E; Zipp F
Best Pract Res Clin Anaesthesiol; 2010 Dec; 24(4):551-62. PubMed ID: 21619866
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
4. Natalizumab treatment in pediatric multiple sclerosis: a case report.
Borriello G; Prosperini L; Luchetti A; Pozzilli C
Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
[TBL] [Abstract][Full Text] [Related]
5. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
6. [Natalizumab in the treatment of multiple sclerosis].
Horga A; Horga de la Parte JF
Rev Neurol; 2007 Sep 1-15; 45(5):293-303. PubMed ID: 17876741
[TBL] [Abstract][Full Text] [Related]
7. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
Jilek S; Jaquiéry E; Hirsch HH; Lysandropoulos A; Canales M; Guignard L; Schluep M; Pantaleo G; Du Pasquier RA
Lancet Neurol; 2010 Mar; 9(3):264-72. PubMed ID: 20117055
[TBL] [Abstract][Full Text] [Related]
8. [Therapy of multiple sclerosis].
Simó M
Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
[TBL] [Abstract][Full Text] [Related]
9. Axonal degeneration is an early pathological feature in autoimmune-mediated demyelination in mice.
Onuki M; Ayers MM; Bernard CC; Orian JM
Microsc Res Tech; 2001 Mar; 52(6):731-9. PubMed ID: 11276125
[TBL] [Abstract][Full Text] [Related]
10. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
11. Immunological markers of optimal response to natalizumab in multiple sclerosis.
Villar LM; García-Sánchez MI; Costa-Frossard L; Espiño M; Roldán E; Páramo D; Lucas M; Izquierdo G; Álvarez-Cermeño JC
Arch Neurol; 2012 Feb; 69(2):191-7. PubMed ID: 22332187
[TBL] [Abstract][Full Text] [Related]
12. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
13. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
Bennett JL
Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056
[TBL] [Abstract][Full Text] [Related]
14. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
15. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement.
Vukusic S; Ionescu I; El-Etr M; Schumacher M; Baulieu EE; Cornu C; Confavreux C;
J Neurol Sci; 2009 Nov; 286(1-2):114-8. PubMed ID: 19758607
[TBL] [Abstract][Full Text] [Related]
16. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
Engelhardt B; Kappos L
Neurodegener Dis; 2008; 5(1):16-22. PubMed ID: 18075270
[TBL] [Abstract][Full Text] [Related]
17. [Disease modifying therapies in multiple sclerosis].
Fukaura H
Nihon Rinsho; 2014 Nov; 72(11):2015-22. PubMed ID: 25518387
[TBL] [Abstract][Full Text] [Related]
18. Effect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumab.
Rossi S; Motta C; Studer V; De Chiara V; Barbieri F; Monteleone F; Fornasiero A; Coarelli G; Bernardi G; Cutter G; Stüve O; Salvetti M; Centonze D
Eur J Neurol; 2013 Jan; 20(1):87-94. PubMed ID: 22741530
[TBL] [Abstract][Full Text] [Related]
19. Early relapses after the first dose of natalizumab in active multiple sclerosis patients.
Centonze D; Furlan R; Gasperini C; Salvetti M; Battistini L
Mult Scler; 2008 Sep; 14(8):1137-8. PubMed ID: 18701574
[TBL] [Abstract][Full Text] [Related]
20. The role of natalizumab in the treatment of multiple sclerosis.
Coyle PK
Am J Manag Care; 2010 Jun; 16(6 Suppl):S164-70. PubMed ID: 20615052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
